Telix Pharmaceuticals (TLX) H2 2023 earnings summary

Executive summary

• FY2023 revenue rose 214% to AU$502.5M, with positive net profit after tax of AU$5.2M and AU$23.9M operating cash inflow.

• Commercial growth from Illuccix® funded investment in late-stage diagnostics and therapeutics, while manufacturing integration and strategic acquisitions expanded the platform.

Financial highlights

• Revenue was AU$502.5M, up 214% from AU$160.1M in 2022; product revenue was AU$497.1M.

• Gross margin improved to 63% from 59%; gross profit was AU$314.3M.

• Adjusted EBITDA was AU$58.4M versus an adjusted loss of AU$67.8M in 2022; profit after tax was AU$5.2M versus a net loss of AU$104.1M.

• Operating cash inflow was AU$23.9M versus AU$64.0M outflow in 2022; cash balance reached AU$123.2M at 31 Dec 2023, up from AU$116.3M.

• External R&D investment was AU$86.3M, in line with plan.

Outlook and guidance

• FY2024 revenue guidance is US$445M–US$465M, or AU$675M–AU$705M at current exchange rates, representing ~35–40% growth on 2023.

• Guidance is based on worldwide Illuccix® sales, with potential upside from Zircaix™ and Pixclara™ subject to regulatory approvals.

• R&D investment is expected to increase 40–50% versus 2023, funded by operating cash flow and broadly in line with revenue growth.

• Planned investment includes launch preparation for Zircaix™ and Pixclara™, ProstACT GLOBAL and additional therapeutic trials, plus Illuccix® indication expansion and life-cycle management.